Hangzhou Tigermed Consulting Co., Ltd
300347
Classificação em ações
#3217
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Preço da ação
$7.44
Valor de mercado
$5.49B
Variação (1 dia)
-2.99%
Variação (1 ano)
-0.42%
País
CN
Negociar Hangzhou Tigermed Consulting Co., Ltd (300347)
Categoria
Healthcare
Rácio P/E de Hangzhou Tigermed Consulting Co., Ltd (300347)
Rácio P/E em October 2026 TTM: 620.75
De acordo com os últimos relatórios financeiros e o preço das ações da Hangzhou Tigermed Consulting Co., Ltd, o rácio P/E atual (TTM) é 620.75. No final de 2024, a empresa tinha um P/E de 116.35.
Histórico do rácio P/E da Hangzhou Tigermed Consulting Co., Ltd de 2009 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 620.75 | 1,038.57% |
| 2025 | 54.52 | -53.14% |
| 2024 | 116.35 | 413.51% |
| 2023 | 22.66 | -49.84% |
| 2022 | 45.17 | 16.64% |
| 2021 | 38.73 | -47.52% |
| 2020 | 73.79 | 32.05% |
| 2019 | 55.89 | 34.74% |
| 2018 | 41.48 | -28.95% |
| 2017 | 58.37 | -35.18% |
| 2016 | 90.05 | 5.48% |
| 2015 | 85.38 | 63.88% |
| 2014 | 52.10 | -27.90% |
| 2013 | 72.26 | 92.73% |
| 2012 | 37.49 | -10.84% |
| 2011 | 42.05 | -32.77% |
| 2010 | 62.55 | -71.25% |
| 2009 | 217.57 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 30.83 | -95.03% |
US
|
|
| -29.16 | -104.70% |
US
|
|
| -25.99 | -104.19% |
AU
|
|
| 22.43 | -96.39% |
BE
|
|
| 31.22 | -94.97% |
NL
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.